Efficacy of once-daily extended-release topiramate (USL255): A subgroup analysis based on the level of treatment resistance

Authors

R. Edward Hogan, Washington University School of Medicine in St. LouisFollow
Ilan Blatt, Chaim Sheba Medical Center
Balduin Lawson, Hospital Dr. Sotero del Rio
Venkatesh Nagaraddi, Neurological Clinic of Texas
Toufic A. Fakhoury, Bluegrass Epilepsy Research
Bob Anders, Upsher-Smith Laboratories, Inc.
Annie M. Clark, Upsher-Smith Laboratories, Inc.
Dawn Laine, Upsher-Smith Laboratories, Inc.
Mark B. Halvorsen, Upsher-Smith Laboratories, Inc.
Steve S. Chung, Barrow Neurological Institute

Journal

Epilepsy & Behavior

Publication Date

2014

Volume

41

Inclusive Pages

136-139

Document Type

Open Access Publication

DOI

10.1016/j.yebeh.2014.09.061

Rights and Permissions

R. Edward Hogan, et al. 2014. Efficacy of once-daily extended-release topiramate (USL255): A subgroup analysis based on the level of treatment resistance. Epilepsy & Behavior, 41: 136-139. doi:10.1016/j.yebeh.2014.09.061

Recommended Citation

Hogan, R. Edward; Blatt, Ilan; Lawson, Balduin; Nagaraddi, Venkatesh; Fakhoury, Toufic A.; Anders, Bob; Clark, Annie M.; Laine, Dawn; Halvorsen, Mark B.; and Chung, Steve S., "Efficacy of once-daily extended-release topiramate (USL255): A subgroup analysis based on the level of treatment resistance." Epilepsy & Behavior. 41, 136-139. (2014).
https://digitalcommons.wustl.edu/open_access_pubs/3503